<DOC>
	<DOC>NCT01386359</DOC>
	<brief_summary>To describe how Nulojix (belatacept) is used and to determine how often Post-Transplant Lymphoproliferative Disorder (PTLD), Central Nervous System (CNS) PTLD and Progressive Multifocal Leukoencephalopathy (PML), rare and serious complications of transplant treatment, occur in patients taking Nulojix (belatacept) in a real-world setting.</brief_summary>
	<brief_title>Evaluating Nulojix (Belatacept) Long-Term Safety in Transplant</brief_title>
	<detailed_description>Time Perspective: Prospective for the majority of patients who are enrolled at the time they begin Nulojix (belatacept) treatment. Retrospective for any patients receiving Nulojix (belatacept) prior to enrollment into ENLiST Registry</detailed_description>
	<mesh_term>Abatacept</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Adult kidney transplant recipient (age ≥18 years at time of transplant) Kidneyonly transplant recipient Positive EBV serostatus a) EBV serostatus negative or unknown included per the investigator discretion Received first dose of Nulojix (Belatacept) within ≤ 14 days of renal transplant Received first dose of Nulojix (Belatacept) as part of normal clinical care (i.e. not as part of a clinical trial) Received Nulojix (belatacept) for non kidney transplants &lt;18 years of age at time of transplant Received first dose of Nulojix (belatacept) as an assigned study drug under a clinical trial protocol EBVserostatus negative or unknown patients, except by investigator decision Patient who did not receive Belatacept for de novo treatment Recipient of concurrent or extant nonkidney organ transplant Received first dose of Nulojix (belatacept) &gt; 14 days after date of renal transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>